CA2239183C - Segments de liaison hydrazone ramifies - Google Patents

Segments de liaison hydrazone ramifies Download PDF

Info

Publication number: CA2239183C
Authority: CA; Canada
Prior art keywords: integer; formula; conjugate; drug; moiety
Prior art date: 1995-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002239183A

Other languages

English (en)

Other versions

CA2239183A1 (fr

Inventor

Dalton King

Raymond A. Firestone

Pamela Trail

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-22

Filing date

1996-12-17

Publication date

2006-08-29

1996-12-17 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

1996-12-17 Priority claimed from PCT/US1996/020513 external-priority patent/WO1997023243A1/fr

1997-07-03 Publication of CA2239183A1 publication Critical patent/CA2239183A1/fr

2006-08-29 Application granted granted Critical

2006-08-29 Publication of CA2239183C publication Critical patent/CA2239183C/fr

2016-12-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000003814 drug Substances 0.000 claims abstract description 129
229940079593 drug Drugs 0.000 claims abstract description 128
239000003446 ligand Substances 0.000 claims abstract description 64
230000008685 targeting Effects 0.000 claims abstract description 31
150000001875 compounds Chemical class 0.000 claims description 77
206010028980 Neoplasm Diseases 0.000 claims description 55
125000003396 thiol group Chemical group [H]S* 0.000 claims description 55
108060003951 Immunoglobulin Proteins 0.000 claims description 25
102000018358 immunoglobulin Human genes 0.000 claims description 25
239000012634 fragment Substances 0.000 claims description 20
-1 3-cyano-4-morpholinyl Chemical group 0.000 claims description 18
230000027455 binding Effects 0.000 claims description 18
229940045799 anthracyclines and related substance Drugs 0.000 claims description 14
239000003817 anthracycline antibiotic agent Substances 0.000 claims description 13
238000006845 Michael addition reaction Methods 0.000 claims description 11
229910052757 nitrogen Inorganic materials 0.000 claims description 11
125000006850 spacer group Chemical group 0.000 claims description 10
201000011510 cancer Diseases 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
125000000468 ketone group Chemical group 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 9
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 8
125000001183 hydrocarbyl group Chemical group 0.000 claims description 8
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
108010051479 Bombesin Proteins 0.000 claims description 6
102100036519 Gastrin-releasing peptide Human genes 0.000 claims description 6
125000004429 atom Chemical group 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
229910052760 oxygen Inorganic materials 0.000 claims description 5
BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 claims description 4
108090001090 Lectins Proteins 0.000 claims description 4
102000004856 Lectins Human genes 0.000 claims description 4
101800003344 Vaccinia growth factor Proteins 0.000 claims description 4
DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 claims description 4
125000001072 heteroaryl group Chemical group 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
239000002523 lectin Substances 0.000 claims description 4
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
208000023275 Autoimmune disease Diseases 0.000 claims description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
102000004862 Gastrin releasing peptide Human genes 0.000 claims description 3
108090001053 Gastrin releasing peptide Proteins 0.000 claims description 3
108010052343 Gastrins Proteins 0.000 claims description 3
102000004877 Insulin Human genes 0.000 claims description 3
108090001061 Insulin Proteins 0.000 claims description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
108010002350 Interleukin-2 Proteins 0.000 claims description 3
102000000588 Interleukin-2 Human genes 0.000 claims description 3
102000004889 Interleukin-6 Human genes 0.000 claims description 3
108090001005 Interleukin-6 Proteins 0.000 claims description 3
102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 3
108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 3
102000013275 Somatomedins Human genes 0.000 claims description 3
102000004338 Transferrin Human genes 0.000 claims description 3
108090000901 Transferrin Proteins 0.000 claims description 3
235000014633 carbohydrates Nutrition 0.000 claims description 3
150000001720 carbohydrates Chemical class 0.000 claims description 3
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 claims description 3
125000005842 heteroatom Chemical group 0.000 claims description 3
229940125396 insulin Drugs 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 3
125000001624 naphthyl group Chemical group 0.000 claims description 3
230000001717 pathogenic effect Effects 0.000 claims description 3
125000004076 pyridyl group Chemical group 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
239000012581 transferrin Substances 0.000 claims description 3
230000003612 virological effect Effects 0.000 claims description 3
231100000409 cytocidal Toxicity 0.000 claims description 2
230000000445 cytocidal effect Effects 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims 12
239000001257 hydrogen Substances 0.000 claims 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 4
150000002431 hydrogen Chemical class 0.000 claims 3
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
102100021022 Gastrin Human genes 0.000 claims 2
102100037571 Neurosecretory protein VGF Human genes 0.000 claims 2
101710098940 Pro-epidermal growth factor Proteins 0.000 claims 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 2
101800001863 Variola growth factor Proteins 0.000 claims 2
OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 claims 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract description 128
229960004679 doxorubicin Drugs 0.000 abstract description 23
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 181
239000000562 conjugate Substances 0.000 description 150
238000006243 chemical reaction Methods 0.000 description 67
238000005160 1H NMR spectroscopy Methods 0.000 description 58
125000005647 linker group Chemical group 0.000 description 56
238000004949 mass spectrometry Methods 0.000 description 54
238000002390 rotary evaporation Methods 0.000 description 52
210000004027 cell Anatomy 0.000 description 48
238000000921 elemental analysis Methods 0.000 description 47
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
239000000427 antigen Substances 0.000 description 43
108091007433 antigens Proteins 0.000 description 43
102000036639 antigens Human genes 0.000 description 43
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 35
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 34
239000006260 foam Substances 0.000 description 34
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
239000002904 solvent Substances 0.000 description 32
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 30
239000012044 organic layer Substances 0.000 description 30
239000011734 sodium Substances 0.000 description 28
238000000034 method Methods 0.000 description 27
239000000243 solution Substances 0.000 description 26
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
239000007787 solid Substances 0.000 description 25
230000000259 anti-tumor effect Effects 0.000 description 23
239000000047 product Substances 0.000 description 23
229920006395 saturated elastomer Polymers 0.000 description 23
241000282414 Homo sapiens Species 0.000 description 18
238000000338 in vitro Methods 0.000 description 18
101150041968 CDC13 gene Proteins 0.000 description 16
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
229940127121 immunoconjugate Drugs 0.000 description 16
230000001588 bifunctional effect Effects 0.000 description 15
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 14
239000000741 silica gel Substances 0.000 description 14
229910002027 silica gel Inorganic materials 0.000 description 14
229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
235000019439 ethyl acetate Nutrition 0.000 description 13
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
238000003818 flash chromatography Methods 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 11
150000007857 hydrazones Chemical group 0.000 description 11
239000012264 purified product Substances 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 10
238000011160 research Methods 0.000 description 10
238000003756 stirring Methods 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 9
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
238000001035 drying Methods 0.000 description 9
230000000694 effects Effects 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
230000003389 potentiating effect Effects 0.000 description 9
239000002244 precipitate Substances 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
229910052938 sodium sulfate Inorganic materials 0.000 description 9
235000011152 sodium sulphate Nutrition 0.000 description 9
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 9
108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
241001529936 Murinae Species 0.000 description 8
238000001914 filtration Methods 0.000 description 8
229940072221 immunoglobulins Drugs 0.000 description 8
150000001299 aldehydes Chemical class 0.000 description 7
210000004408 hybridoma Anatomy 0.000 description 7
239000000543 intermediate Substances 0.000 description 7
210000004072 lung Anatomy 0.000 description 7
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
201000009030 Carcinoma Diseases 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
206010009944 Colon cancer Diseases 0.000 description 5
102100024952 Protein CBFA2T1 Human genes 0.000 description 5
239000012267 brine Substances 0.000 description 5
230000021615 conjugation Effects 0.000 description 5
238000010276 construction Methods 0.000 description 5
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 4
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
QWJIUYWHYILJMQ-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)butanoic acid Chemical compound CCC(C(O)=O)N1C(=O)C=CC1=O QWJIUYWHYILJMQ-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
150000008064 anhydrides Chemical class 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
239000003431 cross linking reagent Substances 0.000 description 4
231100000135 cytotoxicity Toxicity 0.000 description 4
230000003013 cytotoxicity Effects 0.000 description 4
239000004220 glutamic acid Substances 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 4
DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 4
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000012043 crude product Substances 0.000 description 3
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
238000010828 elution Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
239000010410 layer Substances 0.000 description 3
125000000896 monocarboxylic acid group Chemical group 0.000 description 3
238000010188 recombinant method Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000006722 reduction reaction Methods 0.000 description 3
241000894007 species Species 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
SZQVEOLVJHOCMY-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)hexanoic acid Chemical compound CCCCC(C(O)=O)N1C(=O)C=CC1=O SZQVEOLVJHOCMY-UHFFFAOYSA-N 0.000 description 2
MDNSLPICAWKNAG-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical compound OC(=O)C(C)N1C(=O)C=CC1=O MDNSLPICAWKNAG-UHFFFAOYSA-N 0.000 description 2
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108700015227 Met(2)-Pro(5)-(N(1,5)-2,3,4,6-O-tetraacetylglycosyl)- enkephalinamide Proteins 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
229940009456 adriamycin Drugs 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000010549 co-Evaporation Methods 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
208000037841 lung tumor Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
231100000682 maximum tolerated dose Toxicity 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
OBMJQRLIQQTJLR-USGQOSEYSA-N n-[(e)-[1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\CO)=N\NC(=O)CCCCCN1C(C=CC1=O)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 OBMJQRLIQQTJLR-USGQOSEYSA-N 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
150000003568 thioethers Chemical class 0.000 description 2
UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
PVFCXMDXBIEMQG-JTQLQIEISA-N (2s)-2-(phenylmethoxycarbonylamino)pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 PVFCXMDXBIEMQG-JTQLQIEISA-N 0.000 description 1
INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
UTRLJOWPWILGSB-UHFFFAOYSA-N 1-[(2,5-dioxopyrrol-1-yl)methoxymethyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1COCN1C(=O)C=CC1=O UTRLJOWPWILGSB-UHFFFAOYSA-N 0.000 description 1
SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
NITXODYAMWZEJY-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanehydrazide Chemical compound NNC(=O)CCSSC1=CC=CC=N1 NITXODYAMWZEJY-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
239000012623 DNA damaging agent Substances 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
108010066486 EGF Family of Proteins Proteins 0.000 description 1
102000018386 EGF Family of Proteins Human genes 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000008857 Ferritin Human genes 0.000 description 1
108050000784 Ferritin Proteins 0.000 description 1
238000008416 Ferritin Methods 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
238000006165 Knowles reaction Methods 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
235000015107 ale Nutrition 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000003302 anti-idiotype Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000611 antibody drug conjugate Substances 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
229930188550 carminomycin Natural products 0.000 description 1
XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229950001725 carubicin Drugs 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013522 chelant Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000009096 combination chemotherapy Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
239000013058 crude material Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
229960000958 deferoxamine Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
238000012637 gene transfection Methods 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229940125645 monoclonal antibody drug Drugs 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000012856 packing Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
238000005325 percolation Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000000063 preceeding effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940049567 tetradox Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
238000010792 warming Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA002239183A 1995-12-22 1996-12-17 Segments de liaison hydrazone ramifies Expired - Lifetime CA2239183C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US910095P	1995-12-22	1995-12-22
US60/009,100		1995-12-22
PCT/US1996/020513 WO1997023243A1 (fr)	1995-12-22	1996-12-17	Segments de liaison hydrazone ramifies

Publications (2)

Publication Number	Publication Date
CA2239183A1 CA2239183A1 (fr)	1997-07-03
CA2239183C true CA2239183C (fr)	2006-08-29

Family

ID=29405601

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002239183A Expired - Lifetime CA2239183C (fr)	1995-12-22	1996-12-17	Segments de liaison hydrazone ramifies

Country Status (1)

Country	Link
CA (1)	CA2239183C (fr)

1996
- 1996-12-17 CA CA002239183A patent/CA2239183C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2239183A1 (fr)	1997-07-03

Legal Events

Date	Code	Title	Description
2001-12-12	EEER	Examination request
2017-02-20	MKEX	Expiry	Effective date: 20161219

Publication	Publication Date	Title
EP0871490B1 (fr)	2003-03-19	Segments de liaison hydrazone ramifies
EP0328147B1 (fr)	1994-05-11	Immunoconjugués d'anthracyclines à spacer et leurs procédés de préparation
US5137877A (en)	1992-08-11	Bifunctional linking compounds, conjugates and methods for their production
US5622929A (en)	1997-04-22	Thioether conjugates
EP0398305B1 (fr)	1997-03-19	Conjugés d'anthracycline comportant un nouvel agent de liaison et méthodes pour leur production
CA2239183C (fr)	2006-08-29	Segments de liaison hydrazone ramifies
CA2010164C (fr)	2000-08-29	Immunoconjugats d'anthracycline et methode de production
HK1005018B (en)	1998-12-18	Anthracycline conjugates having a novel linker and methods for their production